Development of a test to guide breast cancer treatment

The DDRD Breast Assay has been developed by Almac Diagnostics to help clinicians and patients decide on whether the use of chemotherapy may be an appropriate approach following surgery for early stage node negative breast cancer patients. Patients who are called “positive” are approximately 4 times less likely to have a relapse compared to patients who are called “negative” by the test. This type of information is extremely valuable to both clinicians and patients as it allows a much more informed decision to be made on whether an individual patient is likely to benefit from standard of care chemotherapy.
During the course of this project the DDRD Breast Assay will undergo further analytical and clinically validation to gain CE marking. On approval from the MHRA, it will be launched in the UK private health market and a DDRD Breast Registry established. Suitable clinical validation, analytical validation, clinical utility and cost effectiveness evidence will be gathered to support a submission to NICE with a view to launching this test in the Public UK health market.